Published in Neoplasia on August 01, 2006
SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell (2007) 4.46
SUMOylation and De-SUMOylation: wrestling with life's processes. J Biol Chem (2008) 3.22
Growth control by intracellular tension and extracellular stiffness. Trends Cell Biol (2008) 1.93
The nuclear envelope environment and its cancer connections. Nat Rev Cancer (2012) 1.68
Deubiquitinating enzymes as novel anticancer targets. Future Oncol (2007) 1.43
SUMO Losing Balance: SUMO Proteases Disrupt SUMO Homeostasis to Facilitate Cancer Development and Progression. Genes Cancer (2010) 1.42
Sumo-1 function is dispensable in normal mouse development. Mol Cell Biol (2008) 1.37
Distribution and paralogue specificity of mammalian deSUMOylating enzymes. Biochem J (2010) 1.33
Sumoylation and human disease pathogenesis. Trends Biochem Sci (2009) 1.29
SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem (2010) 1.29
Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities. Protein Sci (2008) 1.26
Post-translational modifications of nuclear receptors and human disease. Nucl Recept Signal (2012) 1.23
DeSUMOylating isopeptidase: a second class of SUMO protease. EMBO Rep (2012) 1.18
The defective nuclear lamina in Hutchinson-gilford progeria syndrome disrupts the nucleocytoplasmic Ran gradient and inhibits nuclear localization of Ubc9. Mol Cell Biol (2011) 1.09
Repression of the SUMO-specific protease Senp1 induces p53-dependent premature senescence in normal human fibroblasts. Aging Cell (2008) 1.09
Sumoylation and regulation of cardiac gene expression. Circ Res (2010) 1.08
Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLoS One (2012) 1.02
Signaling inputs to progesterone receptor gene regulation and promoter selectivity. Mol Cell Endocrinol (2009) 0.98
Androgen receptor abnormalities in castration-recurrent prostate cancer. Expert Rev Endocrinol Metab (2009) 0.97
The in vivo role of androgen receptor SUMOylation as revealed by androgen insensitivity syndrome and prostate cancer mutations targeting the proline/glycine residues of synergy control motifs. J Biol Chem (2012) 0.96
Small ubiquitin-related modifier (SUMO)-1 promotes glycolysis in hypoxia. J Biol Chem (2010) 0.95
Control of progesterone receptor transcriptional synergy by SUMOylation and deSUMOylation. BMC Mol Biol (2012) 0.94
Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. Endocr Relat Cancer (2009) 0.94
SENP1 deSUMOylates and regulates Pin1 protein activity and cellular function. Cancer Res (2013) 0.90
It takes two to tango: Ubiquitin and SUMO in the DNA damage response. Front Genet (2013) 0.90
Advances in the development of SUMO specific protease (SENP) inhibitors. Comput Struct Biotechnol J (2015) 0.88
Post-translational modifications of the progesterone receptors. J Steroid Biochem Mol Biol (2013) 0.88
Starting and stopping SUMOylation. What regulates the regulator? Chromosoma (2013) 0.88
Tumor-suppressive microRNA-145 induces growth arrest by targeting SENP1 in human prostate cancer cells. Cancer Sci (2015) 0.88
Enhanced desumoylation in murine hearts by overexpressed SENP2 leads to congenital heart defects and cardiac dysfunction. J Mol Cell Cardiol (2011) 0.87
Identification and characterization of a new chemotype of noncovalent SENP inhibitors. ACS Chem Biol (2013) 0.87
Kainate receptor activation induces glycine receptor endocytosis through PKC deSUMOylation. Nat Commun (2014) 0.85
Emerging roles of SUMO modification in arthritis. Gene (2010) 0.84
Sumoylation of hypoxia-inducible factor-1α ameliorates failure of brain stem cardiovascular regulation in experimental brain death. PLoS One (2011) 0.84
Phorbol ester enhances KAI1 transcription by recruiting Tip60/Pontin complexes. Neoplasia (2008) 0.83
Role of SUMO-specific protease 2 in reprogramming cellular glucose metabolism. PLoS One (2013) 0.82
Transcriptional repression of estrogen receptor α signaling by SENP2 in breast cancer cells. Mol Endocrinol (2013) 0.82
A SUMOylation Motif in Aurora-A: Implications for Spindle Dynamics and Oncogenesis. Front Oncol (2011) 0.82
Conformational flexibility and changes underlying activation of the SUMO-specific protease SENP1 by remote substrate binding. Nat Commun (2014) 0.81
Assays for investigating deSUMOylation enzymes. Curr Protoc Mol Biol (2012) 0.80
Sentrin/SUMO specific proteases as novel tissue-selective modulators of vitamin D receptor-mediated signaling. PLoS One (2014) 0.80
Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy. CNS Neurol Disord Drug Targets (2013) 0.80
SUMOylation and SUMO-interacting motif (SIM) of metastasis tumor antigen 1 (MTA1) synergistically regulate its transcriptional repressor function. J Biol Chem (2011) 0.80
SUMOylation of HP1α supports association with ncRNA to define responsiveness of breast cancer cells to chemotherapy. Oncotarget (2016) 0.80
Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer. J Hematol Oncol (2015) 0.80
Roles of ubiquitination and SUMOylation on prostate cancer: mechanisms and clinical implications. Int J Mol Sci (2015) 0.79
SUMO-Specific Protease 2 (SENP2) Is an Important Regulator of Fatty Acid Metabolism in Skeletal Muscle. Diabetes (2015) 0.79
The role of Co²+ in the crystallization of human SENP1 and comments on the limitations of automated refinement protocols. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 0.79
Overexpression of SENP3 in oral squamous cell carcinoma and its association with differentiation. Oncol Rep (2013) 0.79
Network analysis of ChIP-Seq data reveals key genes in prostate cancer. Eur J Med Res (2014) 0.78
Aberrant sumoylation signaling evoked by reactive oxygen species impairs protective function of Prdx6 by destabilization and repression of its transcription. FEBS J (2014) 0.77
Regulation of the Tumor-Suppressor Function of the Class III Phosphatidylinositol 3-Kinase Complex by Ubiquitin and SUMO. Cancers (Basel) (2014) 0.77
Small ubiquitin-like modifier protein-specific protease 1 and prostate cancer. Asian J Androl (2008) 0.76
Genetic Polymorphism of SUMO-Specific Cysteine Proteases - SENP1 and SENP2 in Breast Cancer. Pathol Oncol Res (2016) 0.75
SENP1 regulates PTEN stability to dictate prostate cancer development. Oncotarget (2016) 0.75
Inhibition of p53 deSUMOylation exacerbates puromycin aminonucleoside-induced apoptosis in podocytes. Int J Mol Sci (2014) 0.75
The Role of the Small Ubiquitin-Related Modifier (SUMO) Pathway in Prostate Cancer. Biomolecules (2012) 0.75
Neoplasia: the second decade. Neoplasia (2008) 0.75
A monoclonal antibody against the human SUMO-1 protein obtained by immunization with recombinant protein and CpG-DNA-liposome complex. Monoclon Antib Immunodiagn Immunother (2013) 0.75
Systematic Analysis of the Genetic Variability That Impacts SUMO Conjugation and Their Involvement in Human Diseases. Sci Rep (2015) 0.75
SENP1 Is a Crucial Regulator for Cell Senescence through DeSUMOylation of Bmi1. Sci Rep (2016) 0.75
Downregulation of SENP1 inhibits cell proliferation, migration and promotes apoptosis in human glioma cells. Oncol Lett (2016) 0.75
Allosteric activation of SENP1 by SUMO1 β-grasp domain involves a dock-and-coalesce mechanism. Elife (2016) 0.75
Momordin Ic, a new natural SENP1 inhibitor, inhibits prostate cancer cell proliferation. Oncotarget (2016) 0.75
A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell (1997) 9.01
Combinatorial control of gene expression by nuclear receptors and coregulators. Cell (2002) 8.01
A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J Cell Biol (1996) 7.64
The androgen axis in recurrent prostate cancer. Clin Cancer Res (2004) 6.67
SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell (1998) 6.62
Recycling the cell cycle: cyclins revisited. Cell (2004) 6.04
Prostate cancer. N Engl J Med (2003) 5.91
The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell (2002) 5.80
Minireview: Cyclin D1: normal and abnormal functions. Endocrinology (2004) 5.22
An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell (2001) 4.81
The ubiquitin-like protein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer. EMBO J (1997) 4.80
Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science (1997) 4.37
The polycomb protein Pc2 is a SUMO E3. Cell (2003) 3.91
Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p. J Biol Chem (1997) 3.76
PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene (1996) 3.73
P300 transcriptional repression is mediated by SUMO modification. Mol Cell (2003) 3.67
Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol Cell (2001) 3.56
Ubiquitin-like proteins: new wines in new bottles. Gene (2000) 3.46
PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol Cell Biol (2002) 3.25
Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J (1999) 3.08
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
SUMO-1 modification represses Sp3 transcriptional activation and modulates its subnuclear localization. Mol Cell (2002) 2.93
Enzymes of the SUMO modification pathway localize to filaments of the nuclear pore complex. Mol Cell Biol (2002) 2.85
Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci U S A (2000) 2.79
c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem (2000) 2.71
Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A. Nature (1998) 2.69
The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J (2002) 2.56
An essential yeast gene encoding a homolog of ubiquitin-activating enzyme. J Biol Chem (1995) 2.50
Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J Immunol (1996) 2.47
Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol (2003) 2.45
Differential regulation of sentrinized proteins by a novel sentrin-specific protease. J Biol Chem (2000) 2.34
Association of the human SUMO-1 protease SENP2 with the nuclear pore. J Biol Chem (2002) 2.33
Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J Biol Chem (1998) 2.15
Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J Biol Chem (2006) 2.15
Retracted SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell (2000) 2.12
Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem (2001) 2.11
Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem (1999) 2.00
UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins. Genomics (1996) 2.00
SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities. J Biol Chem (2002) 1.99
SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol (2004) 1.89
Preferential interaction of sentrin with a ubiquitin-conjugating enzyme, Ubc9. J Biol Chem (1997) 1.86
Cyclin-dependent kinases. Chem Rev (2001) 1.82
SUMO-1 protease-1 regulates gene transcription through PML. Mol Cell (2002) 1.80
A novel mammalian Smt3-specific isopeptidase 1 (SMT3IP1) localized in the nucleolus at interphase. Eur J Biochem (2000) 1.75
The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J Biol Chem (2002) 1.57
A new SUMO-1-specific protease, SUSP1, that is highly expressed in reproductive organs. J Biol Chem (2000) 1.56
Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol Cell Biol (2005) 1.55
A novel transcriptional repression domain mediates p21(WAF1/CIP1) induction of p300 transactivation. Mol Cell Biol (2000) 1.51
SUMO-1 conjugation to human DNA topoisomerase II isozymes. J Biol Chem (2000) 1.48
SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage. Proc Natl Acad Sci U S A (2000) 1.47
Molecular mechanism and biological functions of c-Jun N-terminal kinase signalling via the c-Jun transcription factor. Cell Signal (2002) 1.41
Characterization of a novel mammalian SUMO-1/Smt3-specific isopeptidase, a homologue of rat axam, which is an axin-binding protein promoting beta-catenin degradation. J Biol Chem (2001) 1.40
Adenovirus E1A downregulates cJun- and JunB-mediated transcription by targeting their coactivator p300. Mol Cell Biol (1996) 1.40
Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun (2003) 1.36
Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. J Biol Chem (2003) 1.35
Regulation of Pax3 transcriptional activity by SUMO-1-modified PML. Oncogene (2001) 1.35
Recent advances in androgen receptor action. Cell Mol Life Sci (2003) 1.34
Molecular cloning and characterization of human AOS1 and UBA2, components of the sentrin-activating enzyme complex. FEBS Lett (1999) 1.33
Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol (2006) 1.29
Characterization of a second member of the sentrin family of ubiquitin-like proteins. J Biol Chem (1998) 1.28
Differential regulation of c-Jun-dependent transcription by SUMO-specific proteases. J Biol Chem (2005) 1.28
Sumoylation of Pdx1 is associated with its nuclear localization and insulin gene activation. Am J Physiol Endocrinol Metab (2002) 1.23
Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate (2001) 1.23
Physical and functional interactions of histone deacetylase 3 with TFII-I family proteins and PIASxbeta. Proc Natl Acad Sci U S A (2002) 1.16
Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol (2000) 1.14
The adenovirus protein Gam1 interferes with sumoylation of histone deacetylase 1. EMBO Rep (2002) 1.12
Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res (1998) 1.10
A specific lysine in c-Jun is required for transcriptional repression by E1A and is acetylated by p300. EMBO J (2001) 1.09
Androgen receptors in prostate cancer. J Urol (2003) 1.07
Control of NF-kappa B transcriptional activation by signal induced proteolysis of I kappa B alpha. Philos Trans R Soc Lond B Biol Sci (1999) 1.02
Signal transduction mediated by cyclin D1: from mitogens to cell proliferation: a molecular target with therapeutic potential. Cancer Treat Res (2004) 1.02
The aryl hydrocarbon receptor nuclear transporter is modulated by the SUMO-1 conjugation system. J Biol Chem (2002) 0.95
Expression of c-jun oncogene in hyperplastic and carcinomatous human prostate. Urology (2006) 0.86
Induction of transcription through the p300 CRD1 motif by p21WAF1/CIP1 is core promoter specific and cyclin dependent kinase independent. Cell Cycle (2002) 0.84
Significance of high-grade prostatic intraepithelial neoplasia on prostate biopsy. Urol Oncol (2003) 0.84
Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells. Br J Cancer (1998) 0.81
SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell (2007) 4.46
Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A (2009) 4.00
Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med (2012) 3.20
Mutations in myosin light chain kinase cause familial aortic dissections. Am J Hum Genet (2010) 2.67
SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. Mol Cell (2010) 2.52
TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet (2012) 2.50
A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer (2007) 2.35
Cellular senescence in usual type uterine leiomyoma. Fertil Steril (2009) 2.34
Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation (2003) 2.28
Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J Biol Chem (2006) 2.15
Diversity of 16S rRNA genes within individual prokaryotic genomes. Appl Environ Microbiol (2010) 1.93
SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol (2004) 1.89
Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. Am J Pathol (2007) 1.77
Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys (2010) 1.72
A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun (2005) 1.68
Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol (2005) 1.67
Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFkappaB-dependent transcription. Nat Cell Biol (2006) 1.62
Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation (2004) 1.55
Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res (2008) 1.52
Mifepristone inhibits GRβ coupled prostate cancer cell proliferation. J Urol (2012) 1.51
Regulation of DNA repair through deSUMOylation and SUMOylation of replication protein A complex. Mol Cell (2010) 1.50
Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo. Circulation (2004) 1.46
SUMO Losing Balance: SUMO Proteases Disrupt SUMO Homeostasis to Facilitate Cancer Development and Progression. Genes Cancer (2010) 1.42
SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. EMBO J (2009) 1.41
Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells. J Biol Chem (2007) 1.41
Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections. Am J Hum Genet (2013) 1.40
MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol (2012) 1.38
Cell-specific regulation of androgen receptor phosphorylation in vivo. J Biol Chem (2005) 1.38
LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res (2009) 1.34
Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol (2006) 1.29
SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem (2010) 1.29
Differential regulation of c-Jun-dependent transcription by SUMO-specific proteases. J Biol Chem (2005) 1.28
Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res (2013) 1.27
Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk. Curr Hypertens Rep (2008) 1.27
HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res (2011) 1.27
Kaposi's sarcoma-associated herpesvirus K-bZIP represses gene transcription via SUMO modification. J Virol (2005) 1.26
Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action. Circ Res (2010) 1.26
Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med (2008) 1.24
Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc Natl Acad Sci U S A (2008) 1.23
Development and characterization of BAC-end sequence derived SSRs, and their incorporation into a new higher density genetic map for cultivated peanut (Arachis hypogaea L.). BMC Plant Biol (2012) 1.21
Heat shock and Cd2+ exposure regulate PML and Daxx release from ND10 by independent mechanisms that modify the induction of heat-shock proteins 70 and 25 differently. J Cell Sci (2003) 1.20
The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol (2005) 1.19
Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transl Res (2009) 1.17
SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress. J Biol Chem (2010) 1.16
Molecular genetics of hepatocellular neoplasia. Am J Transl Res (2010) 1.16
Regulation of the NEDD8 conjugation system by a splicing variant, NUB1L. J Biol Chem (2003) 1.15
Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol (2010) 1.15
Determination of energy and amino acid digestibility in growing pigs fed corn distillers' dried grains with solubles containing different lipid levels. Arch Anim Nutr (2011) 1.13
Isocitrate-to-SENP1 signaling amplifies insulin secretion and rescues dysfunctional β cells. J Clin Invest (2015) 1.12
SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol Cell (2012) 1.11
Regulation of HMGA1 expression by microRNA-296 affects prostate cancer growth and invasion. Clin Cancer Res (2010) 1.11
HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes. Am J Surg Pathol (2010) 1.11
Redox regulation of the stability of the SUMO protease SENP3 via interactions with CHIP and Hsp90. EMBO J (2010) 1.11
Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol (2004) 1.10
Rare, nonsynonymous variant in the smooth muscle-specific isoform of myosin heavy chain, MYH11, R247C, alters force generation in the aorta and phenotype of smooth muscle cells. Circ Res (2012) 1.10
NF-κB induction of the SUMO protease SENP2: A negative feedback loop to attenuate cell survival response to genotoxic stress. Mol Cell (2011) 1.09
Fusion of human hematopoietic progenitor cells and murine cardiomyocytes is mediated by alpha 4 beta 1 integrin/vascular cell adhesion molecule-1 interaction. Circ Res (2007) 1.09
Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J Cell Mol Med (2008) 1.09
HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Mod Pathol (2010) 1.08
Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol (2008) 1.08
Expression of Long-chain Fatty Acyl-CoA Synthetase 4 in Breast and Prostate Cancers Is Associated with Sex Steroid Hormone Receptor Negativity. Transl Oncol (2010) 1.08
Induction of SENP1 in endothelial cells contributes to hypoxia-driven VEGF expression and angiogenesis. J Biol Chem (2010) 1.06
CRP and the risk of atherosclerotic events. Semin Immunopathol (2009) 1.06
Differential expression of SUMO-specific protease 7 variants regulates epithelial-mesenchymal transition. Proc Natl Acad Sci U S A (2012) 1.05
Profiling and functional analyses of microRNAs and their target gene products in human uterine leiomyomas. PLoS One (2010) 1.05
SUMOylation and de-SUMOylation in response to DNA damage. FEBS Lett (2011) 1.03
Roles of the androgen receptor cofactor p44 in the growth of prostate epithelial cells. J Mol Endocrinol (2006) 1.02
Molecular mechanisms involving prostate cancer racial disparity. Am J Transl Res (2009) 1.02
Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer. Am J Pathol (2010) 1.02
Dispersed oil disrupts microbial pathways in pelagic food webs. PLoS One (2012) 1.01
Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J Mol Endocrinol (2006) 1.01
C-reactive protein: structure affects function. Circulation (2004) 1.00
Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res (2009) 0.99
The pleiotropic effects of statins. Curr Opin Cardiol (2005) 0.99
Proteomics, pathway array and signaling network-based medicine in cancer. Cell Div (2009) 0.99
Copy number and gene expression differences between African American and Caucasian American prostate cancer. J Transl Med (2010) 0.99
De-SUMOylation enzyme of sentrin/SUMO-specific protease 2 regulates disturbed flow-induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction and atherosclerosis. Circ Res (2013) 0.99
Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells. PLoS One (2012) 0.98
Differences in clinicopathologic features of prostate cancer between black and white patients treated in the 1990s and 2000s. Urology (2006) 0.98
Thoracic aortic disease in tuberous sclerosis complex: molecular pathogenesis and potential therapies in Tsc2+/- mice. Hum Mol Genet (2010) 0.96
Differentiation of the ductal epithelium and smooth muscle in the prostate gland are regulated by the Notch/PTEN-dependent mechanism. Dev Biol (2011) 0.96
C-reactive protein and atherothrombosis--beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol (2003) 0.95
Novel mutations of epidermal growth factor receptor in localized prostate cancer. Front Biosci (2006) 0.94
Adenomatoid tumor of the adrenal gland: a clinicopathologic study of 3 cases. Ann Diagn Pathol (2005) 0.94
Impact of socioeconomic factors on prostate cancer outcomes in black patients treated with surgery. Urology (2008) 0.94
Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer. PLoS One (2013) 0.93
Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion. Clin Cancer Res (2011) 0.93
Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Cancer (2006) 0.93
TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth. Endocr Relat Cancer (2014) 0.92
Current mouse and cell models in prostate cancer research. Endocr Relat Cancer (2013) 0.92
Bmp7 functions via a polarity mechanism to promote cloacal septation. PLoS One (2012) 0.91
The expression and function of androgen receptor coactivator p44 and protein arginine methyltransferase 5 in the developing testis and testicular tumors. J Urol (2007) 0.91
Regulation of a novel androgen receptor target gene, the cyclin B1 gene, through androgen-dependent E2F family member switching. Mol Cell Biol (2012) 0.91
Metastatic balloon cell malignant melanoma: a case report and literature review. Int J Clin Exp Pathol (2011) 0.90
Androgen receptor coactivator p44/Mep50 in breast cancer growth and invasion. J Cell Mol Med (2010) 0.90
Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. Prostate (2013) 0.89
The diagnosis and management of cardiovascular disease in cancer patients. Curr Probl Cardiol (2008) 0.89
Molecular genetics of testicular germ cell tumors. Am J Cancer Res (2012) 0.89
Protein signatures for classification and prognosis of gastric cancer a signaling pathway-based approach. Am J Pathol (2011) 0.89
LEF1 identifies androgen-independent epithelium in the developing prostate. Mol Endocrinol (2011) 0.88